Characterization of hepatitis B virus surface antigen and polymerase mutations in liver transplant recipients pre- and post-transplant

American Journal of Transplantation

Volumn 3, Issue 6, 2003, Pages 743-753

  Germer, Jeffrey J ^a   Charlton, Michael R ^a   Ishitani, Michael B ^a   Forehand, Curtis D ^a   Patel, Robin ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adefovir; Famciclovir; Hepatitis B immune globulin (HBIG); Hepatitis B virus (HBV); Hepatitis B virus surface antigen (HBsAg); Lamivudine; Liver transplant; Polymerase; Surface (S) gene; YMDD

Indexed keywords

ADEFOVIR; AZATHIOPRINE; CYCLOSPORIN; DNA POLYMERASE; FAMCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS POLYMERASE; LAMIVUDINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE ANALOG; PREDNISONE; TACROLIMUS; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENZYME;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; SERUM; TREATMENT FAILURE;

CHRONIC DISEASE; DNA-DIRECTED DNA POLYMERASE; HEPATITIS B SURFACE ANTIGENS; HUMANS; LIVER TRANSPLANTATION; MUTATION;

EID: 0038545627     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.00149.x     Document Type: Article

References (66)

1. Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1985; 317: 489-495.
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.
3. Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem 1987; 56: 651-693.
4. Lau JY, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 1993; 342: 1335-1340.
5. Okamoto H, Imai M, Kametani M, Nakamura T, Mayumi M. Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. Jpn J Exp Med 1987; 57: 231-236.
6. Sterneck M, Gunther S, Gerlach J et al. Hepatitis B virus sequence changes evolving in liver transplant recipients with fulminant hepatitis. J Hepatol 1997; 26: 754-764.
7. Le Bouvier GL. The heterogeneity of Australia antigen. J Infect Dis 1971; 123: 671-675.
8. Okamoto H, Tsuda F, Sakugawa H et al. Typing hepatitis B virus by homology in nucleotide sequence, comparison of surface antigen subtypes. J Gen Virol 1988; 69: 2575-2583.
9. Stuyver L, De Gendt S, Van Geyt C et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81 (Part 1): 67-74.
10. Norder H, Courouce AM, Magnius LO. Molecular basis of hepatitis B virus serotype variations within the four major subtypes. J Gen Virol 1992; 73: 3141-3145.
11. Magnius LO, Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995; 38: 24-34.
12. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122: 1756-62.
13. Zollner B, Petersen J, Schroter M, Laufs R, Schoder V, Feucht HH. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001; 357: 934-935.
14. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-559.
15. Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999; 179: 775-782.
16. Ding X, Mizokami M, Yao G et al. Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China Intervirol 2001; 44: 43-47.
17. Orito E, Mizokami M, Sakugawa H et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001; 33: 218-223.
18. Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002; 40: 1207-1209.
19. Sumi H, Yokosuka O, Seki N et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003; 37: 19-26.
20. Van Geyt C, Gendt SD, Rombout A et al. A line probe assay for hepatitis B virus genotypes. In: Schinazi RF, Sommadossi J-P, Thomas HC, eds. Therapies for Viral Hepatitis. London: International Medical Press; 1998: pp 139-145.
21. Carman WF, Zanetti AR, Karayiannis P et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336: 325-329.
22. Waters JA, Brown SE, Steward MW, Howard CR, Thomas HC. Analysis of the antigenic epitopes of hepatitis B surface antigen involved in the induction of a protective antibody response. Virus Res 1992; 22: 1-12.
23. Waters JA, O'Rourke SM, Richardson SC, Papaevangelou G, Thomas HC. Qualitative analysis of the humoral immune response to the 'a' determinant of HBs antigen after inoculation with plasma-derived or recombinant vaccine, J Med Virol 1987; 21: 155-160.
24. Protzer-Knolle U, Naumann U, Bartenschlager R et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27: 254-263.
25. Carman WF, Owsianka A, Wallace LA, Dow BC, Mutimer DJ. Antigenic characterization of pre- and post-liver transplant hepatitis B surface antigen sequences from patients treated with hepatitis B immune globulin. J Hepatol 1999; 31: 195-201.
26. Shields PL, Owsianka A, Carman WF et al. Selection of hepatitis B surface 'escape' mutants during passive immune prophylaxis following liver transplantation: potential impact of genetic changes on polymerase protein function. Gut 1999; 45: 306-309.
27. Oon CJ, Lim GK, Ye Z et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 1995; 13: 699-702.
28. Lee PI, Lee CY, Huang LM, Chen JM, Chang MH. A follow-up study of combined vaccination with plasma-derived and recombinant hepatitis B vaccines in infants. Vaccine 1995; 13: 1685-1689.
29. Andre FE. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990; 8 (Suppl.): S74-S78.
30. Whittle HC, Maine N, Pilkington J, Mendy M, Fortuin M, Bunn J et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 1995; 345: 1089-1092.
31. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 1189-1195.
32. Sawyer RG, McGory RW, Gaffey MJ et al. Improved clinical outcomes with liver transplantation for hepatitis B- induced chronic liver failure using passive immunization. Ann Surg 1998; 227: 841-850.
33. Cooreman MP, Leroux-Roels G, Paulij WP. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 2001; 8: 237-247.
34. Wilson JN, Nokes DJ, Carman WF. The predicted pattern of emergence of vaccine-resistant hepatitis B. A cause for concern? Vaccine 1999; 17: 973-978.
35. Hou JL, Wang ZH, Cheng JJ et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology 2001; 34: 1027-1034.
36. Weinberger KM, Kreuzpaintner EA, Hottentrager B, Neiffer S, Jilg W. Mutations in the S gene of hepatitis B virus isolates from chronic carriers with anti-HBc as the only serological marker of HBV infection. In: Rizzetto M, Purcell RH, Gerin JL, Verme G, eds. Viral Hepatitis and Liver Disease. Turin: Minerva Medica; 1997. pp 138-143.
37. Carman WF, Mimms LT. Pre-S/S gene variants. In: Rizzetto M, Purcell RH, Gerin JL, Verme G, eds. Viral Hepatitis and Liver Disease. Turin: Minerva Medica; 1997. pp 108-115.
38. Ireland JH, O'Donnell B, Basuni AA et al. Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays. Hepatology 2000; 31: 1176-1182.
39. de Man RA, Bartholomeusz AI, Niesters HG, Zondervan PE, Locarnini SA. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B. Hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol 1998; 29: 669-675.
40. Tillmann HL, Trautwein C, Bock T et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 1999; 30: 244-256.
41. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-1677.
42. Bartholomeusz A, Groenen LC, Locarnini SA. Clinical experience with famciclovir against hepatitis B virus. Intervirology 1997; 40: 337-342.
43. Xiong X, Yang H, Westland CE, Zou R, Gibbs CS. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 2000; 31: 219-224.
44. Pillay D, Bartholomeusz A, Cane P, Mutimer D, Schinazi RF, Locarnini S. Mutations in the hepatitis B virus DNA polymerase associated with antiviral resistance. Int Antivir News 1998; 6: 167-169.
45. Stuyver LJ, Locarnini SA, Lok A et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33: 751-757.
46. Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998; 66: 493-499.
47. Carman WF, Trautwein C, van Deursen FJ et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24: 489-493.
48. Banerjee K, Guptan RC, Bisht R, Sarin SK, Khandekar P. Identification of a novel surface mutant of hepatitis B virus in a seronegative chronic liver disease patient. Virus Res 1999; 65: 103-109.
49. Ghany MG, Ayola B, Villamil FG et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27: 213-222.
50. Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 1997; 26: 786-791.
51. Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 1999; 30: 1312-1317.
52. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
53. Torresi J, Earnest-Silveira L, Deliyannis G et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002; 293: 305-313.
54. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628-633.
55. Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-1716.
56. Niesters HG, Honkoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus AD. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998; 177: 1382-1385.
57. Buti M,Jardi R, Cotrina M, Rodriguez-Frias F, Esteban R, Guardia J. Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. J Hepatol 1998; 28: 510-513.
58. Westland CE, Yang H, Delaney WE, IV et al. Week 48 resistance surveillance in chronic hepatitis B patients enrolled in a phase III clinical study of adefovir dipivoxil. Hepatology 2001; 34: 447A.
59. Yang H, Westland CE, Delaney WE, IV et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36: 464-473.
60. Torresi J, Earnest-Silveira L, Civitico G et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the 'fingers' subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002; 299: 88-99.
61. Bock CT, Tillmann HL, Torresi J et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122: 264-273.
62. van der Eijk AA, Niesters HG, Pas SD, de Man RA. Persistence of YMDD variants after withdrawal of Lamivudine. J Hepatol 2002; 36: 304-305.
63. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998-1002.
64. Niesters HG, de Man RA, Pas SD, Fries E, Osterhaus AD. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J Med Microbiol 2002; 51: 695-699.
65. Lok AS, Zoulim F, Locarnini S et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002; 40: 3729-3734.
66. Aberle SW, Kletzmayr J, Watschinger B, Schmied B, Vetter N, Puchhammer-Stockl E. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J Clin Microbiol 2001; 39: 1972-1974.